|Day Low/High||16.76 / 17.42|
|52 Wk Low/High||9.16 / 17.55|
Bristol-Myers Squibb Company (NYSE:BMY) and Nektar Therapeutics (Nasdaq:NKTR) today announced a new clinical collaboration to evaluate Bristol-Myers Squibb's Opdivo (nivolumab) with Nektar's investigational...
Backed by the government, initiatives to develop and popularize non-opioid painkillers can make investors high on profits.
Biotech stocks dominate our list of top charts today. Here are four to watch.
The big issue is if the market can build on Friday's jobs good news.
The bears are trying it out on the Bank of England news today, but they may get squeezed.
Computer programming has found that buying bad-news dips is a consistent winner.
Trade-Ideas LLC identified Nektar Therapeutics (NKTR) as a strong on high relative volume candidate
John Nicholson named Senior Vice President & Chief Operating Officer of Nektar; Gil M. Labrucherie named Senior Vice President & Chief Financial Officer of Nektar
Trade-Ideas LLC identified Nektar Therapeutics (NKTR) as a weak on high relative volume candidate
Doug Kass shares his thoughts on two auto stocks and Facebook.
Nektar Therapeutics (NKTR) stock is declining on Wednesday afternoon despite posting better-than-expected 2015 fourth quarter results after yesterday’s closing bell.
- ADYNOVATE [Antihemophilic Factor (Recombinant), PEGylated], currently FDA-approved for adolescent and adult hemophilia A patients 12 years and older, offers proven prophylaxis with a simple, twice-weekly dosing schedule
Doug Kass looks at Carl Icahn's actions on Apple and the breakout in biotech stocks.
Doug Kass shares his views on the health of the banking sector and why he's buying biotech.
Doug Kass shares his views on why he's staying short of GM and MetLife despite steep declines in both stocks.
New Paper Documents Durable Anti-Tumor Efficacy, Safety and Immune Mechanism of Action of NKTR-214 in Multiple Tumor Models as well as a Favorable Safety Profile in Non-Human Primates (NHPs)
- Topline results find no inhibitors to ADYNOVATE [Antihemophilic Factor (Recombinant), PEGylated], treatment were reported and nearly 73 percent of treated patients experienced zero joint bleeds
Baxalta Incorporated (NYSE:BXLT), a global biopharmaceutical leader dedicated to delivering transformative therapies to patients with orphan diseases and underserved conditions, today announced initial results from a Phase...